Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. announced that, the Company has received the Acceptance Notice issued by the National Medical Products Administration of the PRC (the "NMPA"). The investigational new drug (the "IND") application for Phase I clinical trial of FZ-AD005 antibody drug conjugate for injection (DLL3-BB05 ADC, the "Drug") for the treatment of advanced solid tumors has been accepted. Relevant information is as follows: Drug name: FZ-AD005 antibody drug conjugate for injection, Registration type: Class 1 therapeutic biological products, Application matter: Registration of Clinical Trial of Domestic Production of Pharmaceutical Product Acceptance No.

CXSL2300717, Applicant: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd, Review conclusion: Accepted upon review according to the requirements of Article 32 of the Administrative License Law of the People's Republic of China. In recent years, the Company has built a new Linker-Drug platform ("BB05 Platform") with independent intellectual property rights in respect of small molecule. The Drug is the third new generation antitumor antibody-drug conjugate (ADC) drug on the BB05 Platform.

It is generated by a recombinant anti-DLL3 human mouse chimeric antibody ("DLL3") coupled with BB05. According to the public data, the Drug is currently first topoisomerase inhibitors ADC targeting DLL3. The Drug can bind to DLL3-positive tumor cells and endocytosis, releasing small molecule cytotoxic drugs (topoisomerase I inhibitors) in lysosomes by protease cleavage to kill the tumor cells.

The Drug is intended to be developed for the treatment of advanced solid tumors including but not limited to small cell lung cancer, large cell neuroendocrine carcinoma and prostatic cancer, etc. Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products,and the long cycle and numerous stages in the process, there are uncertainties in drug pre-clinical research, clinical trial and commercialization. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks.

The Company will actively facilitate the above research and development project and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict accordance with relevant regulations.